Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer.

Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer.

[This corrects the article DOI: 10.1371/journal.pone.0089350.].

Bibliographic Details
Main Authors:	Zhiqiang Guo, Xin Wang, Dali Cheng, Zhijun Xia, Meng Luan, Shulan Zhang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5646836?pdf=render

Similar Items

PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
by: Zhiqiang Guo, et al.
Published: (2014-01-01)

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
by: Jinyu Meng, et al.
Published: (2021-10-01)

OX40L–OX40 Signaling in Atopic Dermatitis
by: Masutaka Furue, et al.
Published: (2021-06-01)

The role of OX40-OX40L interactions in experimental colitis
by: Bachler, Marcus A.
Published: (2004)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
by: Mingxia Zhao, et al.
Published: (2019-03-01)

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
by: George Fromm, et al.
Published: (2018-12-01)

Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
by: Chun-Yu Chen, et al.
Published: (2017-05-01)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
by: Deng J, et al.
Published: (2019-09-01)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
by: Dawei Cui, et al.
Published: (2019-01-01)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
by: Maite Alvarez, et al.
Published: (2020-02-01)

High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy
by: Michaela Ramser, et al.
Published: (2018-04-01)

Research advances in the role of OX40/OX40L in the immune pathogenesis of chronic hepatitis
by: QIN Wei
Published: (2018-05-01)

Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma
by: Nusrat Jahan, et al.
Published: (2019-05-01)

OX40/OX40L in systemic lupus erythematosus: Association with disease activity and lupus nephritis
by: Farres Mohamed, et al.
Published: (2011-01-01)

Thérapie ciblée anti-OX40 Ligand dans des modèles murins de Sclérodermie systémique
by: Elhai, Muriel
Published: (2015)

Thérapie ciblée anti-OX40 Ligand dans des modèles murins de Sclérodermie systémique
by: Elhai, Muriel
Published: (2015)

Thérapie ciblée anti-OX40 Ligand dans des modèles murins de Sclérodermie systémique
by: Elhai, Muriel
Published: (2015)

Mast Cell-Derived Exosomes Promote Th2 Cell Differentiation via OX40L-OX40 Ligation
by: Fei Li, et al.
Published: (2016-01-01)

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
by: Elizabeth Ahern, et al.
Published: (2018-06-01)

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
by: Zuqiang Liu, et al.
Published: (2017-03-01)

The OX40/OX40L Axis Regulates T Follicular Helper Cell Differentiation: Implications for Autoimmune Diseases
by: NanNan Fu, et al.
Published: (2021-06-01)

Low-Temperature Activity and PdO-PdOx Transition in Methane Combustion by a PdO-PdOx/γ-Al2O3 Catalyst
by: Anil C. Banerjee, et al.
Published: (2018-06-01)

Comparative Analysis of Immunoactivation by Nanosecond Pulsed Electric Fields and PD-1 Blockade in Murine Hepatocellular Carcinoma
by: Maiweilidan Yimingjiang, et al.
Published: (2020-01-01)

CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival
by: Huazhen Liu, et al.
Published: (2019-02-01)

Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade.
by: Nobuhiro Nakamoto, et al.
Published: (2009-02-01)

Enhancement of the Soluble Form of OX40 and OX40L Costimulatory Molecules but Reduction of the Membrane Form in Type 1 Diabetes (T1D)
by: Jingnan An, et al.
Published: (2019-01-01)

699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models
by: Bo Zhang, et al.
Published: (2020-11-01)

Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma
by: Manh-Cuong Vo, et al.
Published: (2018-06-01)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01)

Expression and significance of OX40/OX40L in peripheral blood of patients with autoimmune hepatitis, primary biliary cholangitis, and their overlap syndrome
by: WANG Weizhao
Published: (2020-12-01)

OX40-OX40L interaction promotes proliferation and activation of lymphocytes via NFATc1 in ApoE-deficient mice.
by: Jinchuan Yan, et al.
Published: (2013-01-01)

OX40L/OX40 Signal Promotes IL-9 Production by Mucosal MAIT Cells During Helicobacter pylori Infection
by: Siqi Ming, et al.
Published: (2021-03-01)

Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death
by: Guo, F., et al.
Published: (2022)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
by: Daixi Ren, et al.
Published: (2020-02-01)

Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin.
by: Huafeng Wei, et al.
Published: (2013-01-01)

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.
by: Hao Liu, et al.
Published: (2018-01-01)

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
by: Patrizia Nanni, et al.
Published: (2018-08-01)

Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma
by: Liming Xia, et al.
Published: (2018-09-01)

PD-L1 blockade for urothelial carcinoma
by: Josephine Kang, et al.
Published: (2017-07-01)

Application of PD-1 Blockade in Cancer Immunotherapy
by: Xiaomo Wu, et al.
Published: (2019-01-01)